Editor's Choice – Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study
The next generation low dose SurVeil PCB demonstrated excellent safety and efficacy up to twenty four months and was non-inferior to the IN.PACT Admiral PCB. (ClinicalTrials registration ID: NCT03241459).
Authors
- Sashi Kilaru
- Peter A. Schneider (ORCID: https://orcid.org/0000-0002-4498-5150)
- Kenneth Rosenfield (ORCID: https://orcid.org/0000-0002-5633-6983)
- Leyla Schweiger
- Marcus Thieme (ORCID: https://orcid.org/0000-0003-1618-0360)
- Alexandra J. Lansky (ORCID: https://orcid.org/0000-0001-8002-7497)
- William Bachinsky
- Katharina Guetl (ORCID: https://orcid.org/0000-0002-1659-7185)
- Thomas Zeller (ORCID: https://orcid.org/0000-0003-2704-3871)
- Andrew Holden (ORCID: https://orcid.org/0000-0002-8170-4960)
- Marianne Brodmann (ORCID: https://orcid.org/0000-0001-6493-3799)
- Ramon L. Varcoe (ORCID: https://orcid.org/0000-0001-5611-6991)
- Robert L. Feldman
- William A. Gray
Institutions
- Main Line Health (US)
- University of California, San Francisco (US)
- Medical University of Graz (AT)
- College of Central Florida (US)
- UPMC Central Pa (US)
- Auckland City Hospital (NZ)
- UNSW Sydney (AU)
- Yale University (US)
- Massachusetts General Hospital (US)
- Lankenau Heart Institute (US)
- Prince of Wales Hospital (AU)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Christ Hospital (US)
- Jena University Hospital (DE)
- Christ Hospital (US)
- Friedrich Schiller University Jena (DE)
Publication Details
- Journal
- European Journal of Vascular and Endovascular Surgery
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1016/j.ejvs.2024.11.351
- Citations
- 4
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 2.29